Management of Fulminant IIH with Acetazolamide-Induced Nephrolithiasis

Immediate Medical Management

• The American Academy of Neurology recommends discontinuing acetazolamide immediately and transitioning to topiramate, which provides similar carbonic anhydrase inhibition for ICP reduction but with a different side effect profile 1
• Topiramate offers dual benefit of carbonic anhydrase inhibition (reducing CSF production) plus appetite suppression for weight loss, as suggested by the Journal of Neurology, Neurosurgery and Psychiatry 2, 1
• The recommended starting dose of topiramate is 25 mg with weekly escalation to 50 mg twice daily, according to Praxis Medical Insights 1

Urgent Surgical Evaluation

• Optic Nerve Sheath Fenestration (ONSF) is specifically recommended as first-line treatment in fulminant cases with rapid visual decline, as indicated by Praxis Medical Insights 1
• ONSF has fewer complications than CSF diversion surgery and must be performed by experienced clinicians, as stated by Praxis Medical Insights 1

Critical Warnings About Topiramate

• Women must be informed that topiramate reduces the efficacy of hormonal contraceptives, as reported by the Journal of Neurology, Neurosurgery and Psychiatry 2, 1
• Topiramate has teratogenic potential and is contraindicated in pregnancy, according to the Journal of Neurology, Neurosurgery and Psychiatry and Praxis Medical Insights 2, 3

Headache Management During Transition

• The American Academy of Neurology recommends using NSAIDs or paracetamol for acute headache, and indomethacin may have a particular advantage due to its ICP-reducing effect, as suggested by Praxis Medical Insights 1, 4
• Opioids should be avoided completely, as they should not be prescribed for headache management in IIH, according to Praxis Medical Insights 1, 3

Critical Pitfalls to Avoid

• Serial lumbar punctures are not recommended for long-term management despite providing temporary relief, as stated by Praxis Medical Insights 1
• Corticosteroids, such as prednisone, are not part of standard IIH treatment and may potentially exacerbate the condition, according to Praxis Medical Insights 3
• Treatment failure rates include worsening vision after stabilization in 34% at 1 year and 45% at 3 years, highlighting the importance of serial visual field testing during medication transition, as reported by Praxis Medical Insights 1